Home > Insider Trading > Filing (0000899243-20-034340)

Filing Details

Accession Number:: 0000899243-20-034340
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-12-17 20:30:12
Reporting Period:: 2020-12-15

Accepted Time:: 2020-12-17 20:30:12
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1703057	Abcellera Biologics Inc.	ABCL	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1352908	R Michael Hayden	C/O Abcellera Biologics Inc. 2215 Yukon Street Vancouver A1 V5Y 0A1		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2020-11-06	270,000	$0.33	985,750	No	4	M	Indirect	See footnote
Common Shares	Acquisiton	2020-12-15	117,647	$0.00	1,103,397	No	4	C	Indirect	See footnote
Common Shares	Acquisiton	2020-12-15	73,665	$20.00	118,245	No	4	P	Indirect	By spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	By spouse

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (right to buy)	Disposition	2020-11-06	270,000	$0.00	270,000	$0.33
Common Shares	Stock Option (right to buy)	Acquisiton	2020-11-18	100,000	$0.00	100,000	$2.76
Common Shares	Convertible Note	Acquisiton	2020-12-11	0	$2,000,000.00	117,647	$0.00
Common Shares	Convertible Note	Disposition	2020-12-15	0	$0.00	117,647	$17.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
540,000	2029-09-11	No	4	M	Indirect
100,000	2030-11-18	No	4	A	Direct
0		No	4	A	Indirect
0		No	4	C	Indirect

Footnotes

These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.
On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.
The exercise price reported above was converted from the Canadian exercise price of CAD $0.43 using an exchange rate of CAD $1.27840 = US $1.00.
50% of the shares subject to such option vest and become exercisable on September 11, 2021 and 50% of the shares subject to such option vest and become exercisable on September 11, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date.
The exercise price reported above was converted from the Canadian exercise price of CAD $3.52 using an exchange rate of CAD $1.27840 = US $1.00.
100% of the shares subject to such option vest and become exercisable on the date of the 2021 annual general meeting of the Issuer, subject to the Reporting Person's continuous service to the Issuer on such date
The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share.
This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.